Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 - 20:50

Alpha Tau Medical has released its financial results for the second quarter of 2026, alongside a corporate update highlighting major progress in its oncology pipeline. The company reported a net loss of $18.2 million for the quarter, compared to a net loss of $15.7 million in the same period last year. Research and development expenses rose to $12.4 million, driven by expanded clinical trial activity and manufacturing scale-up. Cash and cash equivalents stood at $89.5 million as of June 30, 2026.

The most significant clinical news came from the ongoing U.S. recurrent glioblastoma REGAIN trial. Interim data showed a 100% local disease control rate and a 67% complete response rate among evaluable patients. These results prompted the FDA to clear the company to complete enrollment in the study and to add two additional leading U.S. clinical sites. The company believes these data support the potential of Alpha DaRT as a viable treatment option for this difficult-to-treat cancer.

In a separate strategic move, Alpha Tau entered into a collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the United States. Under the agreement, Tolmar will make a $20 million equity investment in Alpha Tau at a 25% premium to the market price. Tolmar will provide $15 million to support expanded U.S. manufacturing capacity. The partnership combines Alpha Tau's proprietary technology with Tolmar's established urology commercial infrastructure.

Management expressed confidence in the company's trajectory, noting that the quarter's achievements position Alpha Tau for potential regulatory submissions in the coming years. The company also reiterated its commitment to advancing its clinical pipeline while maintaining financial discipline. The full financial statements and management commentary are available in the company's SEC filing.